Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release in human peripheral blood mononuclear cells.
EMBO molecular medicine • Vol. 14, Issue 6 • 2022
Olverembatinib: First Approval.
Drugs • Vol. 82, Issue 4 • 2022
The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.
Immunology • Vol. 160, Issue 1 • 2020
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
Cell & bioscience • Vol. 9 • 2019
